SCHEMBL6966951

SCHEMBL6966951

FC(F)(F)Oc1cccc(Oc2ccccc2COCC2CCc3[nH]cnc3C2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.37
ADRA1A P35348 3/20 0.34
SGPL1 O95470 1/20 0.33
S1PR1 P21453 1/20 0.33
SLC6A2 P23975 2/20 0.32
SLC6A3 Q01959 2/20 0.32
SLC6A4 P31645 1/20 0.32
ADRA1D P25100 1/20 0.32
FFAR1 O14842 1/20 0.32
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
BRAF P15056 2/20 0.31
KDR P35968 2/20 0.31
EGFR P00533 1/20 0.31
ERBB2 P04626 1/20 0.31
ERBB3 P21860 1/20 0.31
ERBB4 Q15303 1/20 0.31
ALOX5AP P20292 1/20 0.31
FEN1 P39748 1/20 0.31
DCPS Q96C86 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961834 0.87 ADRA1A (0.40) ADRA1ASLC6A2SLC6A3SLC6A4ADRA1D
SCHEMBL6960596 0.83 SGPL1 (0.43) ADRA1ASGPL1S1PR1KDR
SCHEMBL6967705 0.78 REN (0.34) RENFFAR1DCPS
SCHEMBL6961981 0.77 REN (0.34) RENFFAR1ALOX5APFEN1DCPS
SCHEMBL6966793 0.75 ADRA1A (0.41) ADRA1AADRA1DHTR2CHTR2B
SCHEMBL6957286 0.75 P2RX7 (0.38) ADRA1ASLC6A2SLC6A4ALOX5APFEN1
SCHEMBL6967165 0.74 KDM1A (0.39) ADRA1ASGPL1S1PR1SLC6A3SLC6A4
SCHEMBL6964292 0.74 ADRA1A (0.41) ADRA1AADRA1D
SCHEMBL6954794 0.73 CHRNB2 (0.51) ADRA1ASLC6A2SLC6A3SLC6A4ADRA1D
SCHEMBL6967627 0.73 DRD4 (0.43) SLC6A4HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 REN 951/4885ADRA1A 212/4885SGPL1 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.